Program
Olanzapine
Also written as “olanzapine”, “ALKS 3831” and “Olanzapine Tablets 5 mg”.
Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Treatment-Resistant · Fasting · Borderline Personality Disorder, led by 11 companies.
Drug pageOlanzapine: every studyMany companies study it; this page follows only the 54 they lead. All 266 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 360 open or running | phase 4since Apr 30, 2002 | Apr 30, 2002 | none ahead |
| Viatrisits history only | 50 open or running | phase 4since Oct 12, 2005 | Sep 1, 2005 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 40 open or running | phase 1since Jan 2, 2012 | Jan 2, 2012 | none ahead |
| Abbottits history only | 20 open or running | phase 4since Oct 16, 2003 | Oct 16, 2003 | none ahead |
| AstraZenecaits history only | 10 open or running | phase 3since May 2, 2002 | May 2, 2002 | none ahead |
| HK inno.Nits history only | 10 open or running | phase 4since May 11, 2014 | May 11, 2014 | none ahead |
| Joint Stock Company "Farmak"its history only | 10 open or running | phase 1since Nov 15, 2021 | Nov 15, 2021 | none ahead |
| Neurelisits history only | 10 open or running | phase 1since Sep 6, 2024 | Sep 6, 2024 | none ahead |
| Orexigen Therapeuticsits history only | 10 open or running | phase 2since Aug 12, 2008 | Aug 12, 2008 | none ahead |
| Qilu Pharmaceuticalits history only | 10 open or running | phase 3since Mar 27, 2023 | Mar 27, 2023 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 1since Mar 13, 2024 | Mar 13, 2024 | none ahead |
Also a collaborator on its studies: Pfizer and H. Lundbeck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 22 studies since Apr 30, 2002.
- Nov 28, 2005Phase 3 study in Bipolar Disorder I or IINCT00259272 · 141 enrolled · France
- Dec 15, 2005Phase 3 study in ManiaNCT00266630 · 139 enrolled · Japan
- Mar 15, 2006Phase 4 study in SchizophreniaNCT00303602 · 149 enrolled · United States, Canada, Mexico and more
- Jun 14, 2006Phase 4 study in SchizophreniaNCT00337662 · 628 enrolled · United States, Argentina, Russian Federation
- Nov 17, 2006Phase 4 study in Bipolar I DisorderNCT00402324 · 202 enrolled · United States
- Nov 17, 2006Phase 3 study in SchizophreniaNCT00401973 · 199 enrolled · United States, Brazil, Israel and more
- Jun 11, 2007Phase 4 study in Bipolar DisorderNCT00485771 · 403 enrolled · United States
- Jul 30, 2007Phase 3 study in Bipolar DisorderNCT00510146 · 514 enrolled · China, Japan, Korea, Republic of
- Feb 8, 2008Phase 3 study in Bipolar I DisorderNCT00618748 · 101 enrolled · Japan
- Mar 18, 2008Phase 3 study in SchizophreniaNCT00640510 · 34 enrolled · Japan
- Oct 3, 2008Phase 4 study in Bipolar DisorderNCT00767715 · 11 enrolled · Sweden
- Aug 12, 2009Phase 3 study in Depressive Disorder, Treatment-ResistantNCT00958568 · 892 enrolled · United States, Argentina, India and more
- Sep 1, 2009Phase 3 study in SchizophreniaNCT00970281 · 91 enrolled · Japan
- Sep 7, 2012Phase 3 study in Depressive Disorder, Treatment-ResistantNCT01687478 · 176 enrolled · China
TargetBeta
“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist”ChEMBL 37, by rule
Studies
All 36 Eli Lilly leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01687478Depressive Disorder, Treatment-Resistant · China | 3 | Terminated | Nov 2015 | 176 |
| NCT00970281Schizophrenia · Japan | 3 | Completed | Apr 2011 | 91 |
| NCT00958568Depressive Disorder, Treatment-Resistant · United States, Argentina, India and more | 3 | Completed | Mar 2012 | 892 |
| NCT00767715Bipolar Disorder · Sweden | 4 | Terminated | Apr 2005 | 11 |
| NCT00640510Schizophrenia · Japan | 3 | Completed | Jul 2008 | 34 |
| NCT00618748Bipolar I Disorder · Japan | 3 | Completed | Sep 2010 | 101 |
| NCT00510146Bipolar Disorder · China, Japan, Korea, Republic of | 3 | Completed | Mar 2010 | 514 |
| NCT00485771Bipolar Disorder · United States | 4 | Completed | 403 | |
| NCT00402324Bipolar I Disorder · United States | 4 | Completed | Feb 2008 | 202 |
| NCT00401973Schizophrenia · United States, Brazil, Israel and more | 3 | Completed | Sep 2008 | 199 |
| NCT00337662Schizophrenia · United States, Argentina, Russian Federation | 4 | Completed | Dec 2007 | 628 |
| NCT00303602Schizophrenia · United States, Canada, Mexico and more | 4 | Completed | Dec 2007 | 149 |
| NCT00266630Mania · Japan | 3 | Completed | May 2009 | 139 |
| NCT00259272Bipolar Disorder I or II · France | 3 | Completed | May 2008 | 141 |
| NCT00191997Bipolar Disorder · Spain | 4 | Completed | 180 | |
| NCT00191828Weight Gain · Italy | 4 | Completed | 60 | |
| NCT00191555Schizophrenia · France | 4 | Completed | 360 | |
| NCT00190892Bipolar Disorder · Australia, Greece, Hungary and more | 4 | Completed | 120 | |
| NCT00190749Schizophrenia · United States | 4 | Completed | Jun 2008 | 130 |
| NCT00129220Bipolar Disorder · Japan | 3 | Completed | Jan 2009 | 224 |
| NCT00113594Schizophrenia · United States, Puerto Rico, Russian Federation | 3 | Completed | 100 | |
| NCT00103571Schizophrenia · United States, Puerto Rico | 4 | Completed | 600 | |
| NCT00100776Schizophrenia · United States | 4 | Completed | 600 | |
| NCT00094549Bipolar Disorder · United States, Lithuania, Puerto Rico and more | 4 | Completed | 500 | |
| NCT00091650Borderline Personality Disorder · United States, Belgium, France and more | 3 | Completed | 300 | |
| NCT00090012Schizophrenia · United States | 4 | Completed | 340 | |
| NCT00088491Schizophrenia · Finland, Turkey | 3 | Completed | 1,205 | |
| NCT00088465Schizophrenia · United States, Argentina, Australia and more | 3 | Completed | Dec 2010 | 931 |
| NCT00088049Schizophrenia · United States | 4 | Completed | 560 | |
| NCT00088036Borderline Personality Disorder · United States, Argentina, Poland and more | 3 | Completed | 450 | |
| NCT00051298Schizophrenia · United States, Russian Federation | 3 | Completed | 107 | |
| NCT00050206Bipolar Disorder · United States | 4 | Completed | 130 | |
| NCT00036088Schizophrenia · United States, Argentina, Austria and more | 4 | Completed | 530 | |
| NCT00035321Depressive Disorder, Major · United States, Canada | 3 | Completed | 600 | |
| NCT00034801Depression · United States | 4 | Completed | 378 | |
| NCT00034580Bipolar Disorder · United States | 4 | Completed | 326 |
How it is read
Names in the registry
- “Olanzapine”, 33 entries
- “olanzapine”, 17 entries
- “ALKS 3831”, 7 entries
- “Olanzapine Tablets 5 mg”, 2 entries
- “Olanzapine OD Tablets 5 mg”, 2 entries
Conditions, from the studies’ own filings
- Schizophrenia, 41 studies
- Bipolar Disorder, 12 studies
- Depressive Disorder, Treatment-Resistant, 2 studies
- Fasting, 2 studies
- Borderline Personality Disorder, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.